Where each model wins on economics
Account-gated compounder pricing can win when your entire formulary lives inside Tailor Made's integrative catalog — deep peptides, hormones, and longevity protocols — and you are comfortable committing before seeing per-vial cost. The upside is a direct relationship with a high-volume 503A compounder; the risk is that the rate is unverifiable up front and may pair with ancillary charges for UPS shipping, signature delivery, and card processing that change landed cost. Pass-through pricing wins when a clinic needs to quote cash-pay patients on landed cost before the consult, wants to verify that drug cost is not marked up, and values seeing the number on every SKU before ordering — especially when batching refills across more than one 503A partner in one cart.
Most cash-pay GLP-1 clinics care most about one thing: knowing per-vial cost before they set patient pricing. That single requirement tends to favor a pass-through model, because a clinic agreement that arrives after account approval cannot inform pricing you need to set during evaluation. But a peptide-heavy clinic that only ever orders from Tailor Made and values their integrative formulary may rationally prefer the compounder path — the right answer depends on the clinic, not the marketing.